Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

SUNNYVALE, Calif., Feb. 14, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its six and three months ended December 31, 2012. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the six month period ended December 31, 2012 represents a transition period, with the next fiscal year covering the period from January 1, 2013 through December 31, 2013.

Financial Results for the Six and Three Months Ended December 31, 2012 The GAAP (Generally Accepted Accounting Principles) net income for the six months ended December 31, 2012 was $117.5 million, or $1.69 and $1.58 per basic and diluted earnings per share, respectively, compared with GAAP net income of $41.7 million, or $0.61 and $0.58 per basic and diluted earnings per share, respectively, for the six months ended December 31, 2011.

The GAAP net income for the quarter ended December 31, 2012 was $41.9 million, or $0.60 and $0.56 per basic and diluted earnings per share, respectively, compared to GAAP net income of $56.3 million or $0.82 and $0.78 per basic and diluted earnings per share, respectively, for the three months ended December 31, 2011.

The non-GAAP net income reported for the six months ended December 31, 2012 was $125.0 million, or $1.79 and $1.68 income per basic and diluted earnings per share, respectively, compared with non-GAAP net income of $46.3 million, or $0.68 and $0.65 income per basic and diluted earnings per share, respectively for the six months ended December 31, 2011. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

The non-GAAP net income reported for the quarter ended Dece
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... CHESTER, Pa., April 1, 2008 VWR International,LLC, ... that it,has acquired Jencons (Scientific) Limited, a UK ... the UK,s largest suppliers of laboratory equipment,and consumables ... company also has,operations in Ireland, Kenya and North ...
... and MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris ... a global biopharmaceutical company,focused on endocrine therapy ... a leading Canadian specialty pharmaceutical company, announced ... the transactions under their,previously announced purchase and ...
... 1, 2008 Piedmont Heart Institute (PHI),expands its ... practice, Cardiology of Georgia, P.C. (COG), through a ... With eight,locations including Buckhead, Canton, Fayetteville and North ... the Piedmont Heart Institute and an,important addition to ...
Cached Biology Technology:VWR International, LLC Acquires Jencons (Scientific) Ltd, UK 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... seen the story in the news before. Whether it,s the death ... in August, or of an elderly woman gardening in the middle ... condition for which there is no treatment beyond submersion in ice ... to a normal temperature. But, in a new ...
... of what living cells do is carried out by "molecular ... carry out some biological function. How the minute steps of ... a favorite target for creationists. In a study published ... a team of scientists from the University of Chicago and ...
... warmest since global climate has been measured, and while ... plant communities that reflect this warming trend, no study ... until now. With the publication of "Continent-wide ... Advance Online Publication (AOP) in Nature Climate Change ...
Cached Biology News:'Couch potato pill' might stop heat stroke too 2'Couch potato pill' might stop heat stroke too 3Evolution of complexity recreated using 'molecular time travel' 2Evolution of complexity recreated using 'molecular time travel' 3Evolution of complexity recreated using 'molecular time travel' 4European mountain vegetation shows effects of warmer climate 2
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
Request Info...
Request Info...
Biology Products: